How did Editas Medicine's revenue and expenses trend in Q4 2024?

Editas Medicine's revenue and expenses in Q4 2024 showed a significant decline in net income, with a reported loss of $45.4 million. The company's revenue by segment was $32.31 million, with a separate segment of $1.71 million from Collaboration and Other Research and Development.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|EDIT|EDIT.O|Editas Medicine|20240101-2024|Collaboration and Other Research and Development|3.2314E7|185|
|EDIT|EDIT.O|Editas Medicine|20240101-2024|Collaboration and Other Research and Development|1710000|185|
|EDIT|EDIT.O|Editas Medicine|20240101-2024|Collaboration and Other Research and Development|1649000|185|
|EDIT|EDIT.O|Editas Medicine|20240101-2024|Collaboration and Other Research and Development|1135000|185|
|EDIT|EDIT.O|Editas Medicine|20240101-2024|Collaboration and Other Research and Development|1135000|185|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|EDIT|EDIT.O|Editas Medicine|2024 Q1|-26.335753324088422|-6.195E7|185|
|EDIT|EDIT.O|Editas Medicine|2024 Q2|-67.80094316207496|-6.7607E7|185|
|EDIT|EDIT.O|Editas Medicine|2024 Q3|-38.03283058264289|-6.2141E7|185|
|EDIT|EDIT.O|Editas Medicine|2024 Q4|-140.51605383066652|-4.5395E7|185|

|code|Ticker|Name|Date|Gross PP&E YoY|Gross PP&E|market_code|
|---|---|---|---|---|---|---|
|EDIT|EDIT.O|Editas Medicine|20240331|16.09610463463179|4.0831E7|185|
|EDIT|EDIT.O|Editas Medicine|20240630|18.65815399856899|4.3118E7|185|
|EDIT|EDIT.O|Editas Medicine|20240930|25.663886230001363|4.5949E7|185|
|EDIT|EDIT.O|Editas Medicine|20241231|20.508200146244647|4.6145E7|185|